Some research highlights from the European Association for the Study of the Liver’s 50th International Liver Conference, including a potential cure for hepatitis B virus infections, with a promising new treatment proving 100% successful in pre-clinical models and new hepatitis C virustreatment guidelines.
Potential cure for HBV
A potential cure for hepatitis B virus (HBV) infections, with a promising new treatment proving 100% successful in pre-clinical models.
New HCV treatment guidelines
EASL released its latest hepatitis C virus (HCV) treatment guidelines.
HCV combination therapies show promise
A number of new HCV combination therapies show promise.
NASH has 50% higher death rate than NAFLD
A [b]British[/b] cohort of almost 1m people found that mortality from non-alcoholic steatohepatitis (NASH), over a 14-year period, was approximately 50% higher than for those with non-alcoholic fatty liver disease (NAFLD).
NAFLD promotes coronary artery calcification
NAFLD plays a role in the early stages of coronary atherosclerosis and can also promote the development of coronary artery calcification.
HCV increases cancer risk 'significantly'
Cancer rates in patients with HCV were significantly increased compared to the non-HCV cohort.
In-patient cirrhosis deaths plummet
The largest US sampling to date found 'dramatic improvements' in the survival of patients with cirrhosis and liver failure.
HBV vaccination must be expanded
The universal infant hepatitis B virus (HBV) vaccination needs further expansion to significantly reduce HBV transmission and liver disease mortality.